Tetsuya Taura

Person

Palo Alto, CA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Anti-CD47 combination therapy
- Patent number 11,618,784
- Issue date Apr 4, 2023
- Teva Pharmaceuticals Australia Pty Ltd.
- Sarah Lee Pogue
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
- Patent number 11,117,975
- Issue date Sep 14, 2021
- Teva Pharmaceuticals Australia Pty Ltd.
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fusions of antibodies to CD38 and attenuated interferon alpha
- Patent number 10,981,986
- Issue date Apr 20, 2021
- Teva Pharmaceuticals Australia Pty Ltd.
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
- Patent number 9,963,515
- Issue date May 8, 2018
- Teva Pharmaceuticals Australia Pty Ltd.
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fusions of antibodies to CD38 and attenuated interferon alpha
- Patent number 9,611,322
- Issue date Apr 4, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Modified antibody with improved half-life
- Patent number 9,505,826
- Issue date Nov 29, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- David Wilson
- C07 - ORGANIC CHEMISTRY

Patents Applicationslast 30 patents

Information Patent Application
ANTI-CD47 COMBINATION THERAPY
- Publication number 20220259311
- Publication date Aug 18, 2022
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Sarah Lee Pogue
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-CD47 COMBINATION THERAPY
- Publication number 20200010544
- Publication date Jan 9, 2020
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Sarah Lee POGUE
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
- Publication number 20180305460
- Publication date Oct 25, 2018
- Teva Pharmaceuticals Australia Pty Ltd
- Adam Clarke
- C07 - ORGANIC CHEMISTRY
Information Patent Application
FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA
- Publication number 20170233449
- Publication date Aug 17, 2017
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
POLYPEPTIDE CONSTRUCTS AND USES THEREOF
- Publication number 20160367695
- Publication date Dec 22, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
- Publication number 20160068612
- Publication date Mar 10, 2016
- Teva Pharmaceuticals Australia Pty Ltd
- Adam Clarke
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
POLYPEPTIDE CONSTRUCTS AND USES THEREOF
- Publication number 20140248238
- Publication date Sep 4, 2014
- Teva Pharmaceuticals Australia Pty Ltd
- David S. Wilson
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MODIFIED ANTIBODY WITH IMPROVED HALF-LIFE
- Publication number 20130281677
- Publication date Oct 24, 2013
- Cephalon Australia Pty, Ltd.
- David Wilson
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-PAMP THERAPEUTIC ANTIBODIES
- Publication number 20110301332
- Publication date Dec 8, 2011
- Cephalon Australia (VIC) Pty Ltd.
- David Wilson
- C07 - ORGANIC CHEMISTRY

Tetsuya Taura

Person

Patents Grantslast 30 patents

Anti-CD47 combination therapy

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Fusions of antibodies to CD38 and attenuated interferon alpha

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Fusions of antibodies to CD38 and attenuated interferon alpha

Modified antibody with improved half-life

Patents Applicationslast 30 patents

ANTI-CD47 COMBINATION THERAPY

ANTI-CD47 COMBINATION THERAPY

ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B

FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA

POLYPEPTIDE CONSTRUCTS AND USES THEREOF

ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B

POLYPEPTIDE CONSTRUCTS AND USES THEREOF

MODIFIED ANTIBODY WITH IMPROVED HALF-LIFE

ANTI-PAMP THERAPEUTIC ANTIBODIES